Gynecological Cancer

A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Brain and Nervous System | Breast - Female | Breast - Male | Breast Cancer (ER, PR, and HER2 negative) | Colon | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Lip, Oral Cavity and Pharynx | Lung | Melanoma | Melanoma, skin | Non-Small Cell Lung Cancer (NSCLC) | Other Female Genital | Ovarian Cancer | Ovary | Prostate | Prostate Cancer | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase II Trial of Carboplatin/Paclitaxel with and without Trastuzumab in HER2/neu+ Patients with Advanced orRecurrent Uterine Serous Papillary Cancer
Disease/Condition: Corpus Uteri
Principal Investigator: Alessandro Santin
A Phase III Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
Principal Investigator: Masoud Azodi
A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Principal Investigator: Peter Schwartz
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
Principal Investigator: Thomas Rutherford
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (GOG 0258) (CIRB)
Disease/Condition: Corpus Uteri | Endometrial Cancer
Principal Investigator: Masoud Azodi
A Randomized, Double-Blind, Placebo-Controlled Phase II Study Of Vtx-2337 In Combination With Pegylated Liposomal Doxorubicin (Pld) In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer
Principal Investigator: Alessandro Santin
An Open-label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second line Therapy in Patients With Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Disease/Condition: Bladder | Kidney | Other Urinary
Principal Investigator: Daniel Petrylak
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Disease/Condition: Fallopian Tube Cancer | Other Female Genital | Ovarian Cancer | Ovary | Primary Peritoneal Cavity Cancer
Principal Investigator: Thomas Rutherford
Phase II Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Disease/Condition: Cancer
Principal Investigator: Alessandro Santin
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase III Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Principal Investigator: Thomas Rutherford